Table 2.
Chemotherapy regimens and radiation targets in the entire cohort and in patients with different molecular subtypes of breast cancer.
| Entire cohort | Luminal HER2-negative | Luminal HER2-positive | HER2-overexpressing | Triple-negative | Unknown subtype | |
|---|---|---|---|---|---|---|
| Chemotherapy regimen (N = 5442) | ||||||
| Anthracycline-based | 1126 (20.7) | 618 (21.2) | 87 (13.5) | 70 (17.5) | 143 (21.9) | 208 (25.2) |
| Taxane-based | 301 (5.5) | 144 (4.9) | 43 (6.7) | 10 (2.5) | 60 (9.2) | 44 (5.3) |
| Both | 3245 (59.6) | 1772 (60.7) | 440 (68.2) | 284 (71.0) | 375 (57.3) | 374 (45.4) |
| Other | 204 (3.7) | 77 (2.6) | 8 (1.2) | 7 (1.8) | 24 (3.7) | 88 (10.7) |
| Unknown | 566 (10.4) | 308 (10.6) | 67 (10.4) | 29 (7.2) | 52 (8.0) | 110 (13.3) |
| Chemotherapy cycles | ||||||
| median (range) | 6 (1–21) | 6 (1–20) | 6 (1–9) | 6 (1–21) | 6 (1–13) | 6 (1–10) |
| RT target (N = 1780) | ||||||
| Chest wall | 1642 (92.2) | 799 (93.3) | 188 (91.3) | 136 (92.5) | 234 (95.5) | 283 (87.4) |
| Supra/infraclavicular fossa | 1612 (90.6) | 773 (90.3) | 179 (86.9) | 135 (91.8) | 229 (93.5) | 296 (90.8) |
| Axilla | 146 (8.2) | 46 (5.4) | 12 (5.8) | 9 (6.1) | 22 (9.0) | 57 (17.5) |
| Internal mammary chain | 162 (9.1) | 36 (4.2) | 17 (8.3) | 8 (5.4) | 15 (6.1) | 86 (26.4) |
| Unknown | 84 (4.7) | 43 (2.4) | 13 (0.7) | 4 (0.2) | 5 (0.3) | 19 (1.1) |
RT, radiotherapy.